{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Everolimus", "query": { "condition": "Everolimus" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 364, "total_pages": 37, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Everolimus&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T17:30:47.776Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01215136", "title": "First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transitional Cell Carcinoma", "Bladder Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Galsky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2010-12", "completion_date": "2018-04-24", "has_results": true, "last_update_posted_date": "2023-11-24", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Chicago, Illinois • Bloomington, Indiana + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01215136" }, { "nct_id": "NCT00719264", "title": "Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma", "Adenocarcinoma", "Renal Cell", "Nephroid Carcinoma", "Hypernephroid" ], "interventions": [ { "name": "RAD001(everolimus)", "type": "DRUG" }, { "name": "interferon alfa-2a", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 365, "start_date": "2008-11-12", "completion_date": "2013-04-15", "has_results": true, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 9, "location_summary": "Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 5 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719264" }, { "nct_id": "NCT03328104", "title": "Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "2 Years to 29 Years" }, "enrollment_count": 8, "start_date": "2018-07-24", "completion_date": "2023-06-29", "has_results": false, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03328104" }, { "nct_id": "NCT03697408", "title": "Itacitinib + Everolimus in Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2019-02-11", "completion_date": "2027-06", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03697408" }, { "nct_id": "NCT01111058", "title": "Everolimus Versus Placebo in Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Everolimus (RAD 001)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2010-04", "completion_date": "2018-10", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 17, "location_summary": "Miami, Florida • Chicago, Illinois • Harvey, Illinois + 12 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01111058" }, { "nct_id": "NCT03950609", "title": "Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Carcinoid Tumor", "Digestive System Neuroendocrine Neoplasm", "Multiple Endocrine Neoplasia Type 1", "Neuroendocrine Neoplasm", "Unresectable Carcinoid Tumor" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-07-30", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03950609" }, { "nct_id": "NCT01007942", "title": "Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2/Neu Over-expressing Locally Advanced Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 569, "start_date": "2009-10", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 43, "location_summary": "Tucson, Arizona • La Jolla, California • Greenwood Village, Colorado + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01007942" }, { "nct_id": "NCT00976573", "title": "Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2010-04", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 310, "location_summary": "Scottsdale, Arizona • Martinez, California • Mountain View, California + 214 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Martinez", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976573" }, { "nct_id": "NCT00474929", "title": "Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 103, "start_date": "2007-08-29", "completion_date": "2019-08-08", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Rochester, Minnesota", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474929" }, { "nct_id": "NCT01182168", "title": "Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Renal Pelvis Cancer", "Ureter Cancer" ], "interventions": [ { "name": "gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2010-08", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-03-31", "last_synced_at": "2026-07-23T17:30:47.776Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01182168" } ] }